Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 7—July 2026

Research

Adeno-Associated Virus Type 2 and Human Adenovirus Species F Type 41 Co-infection Associated with Acute Severe Hepatitis in Children, California, USA

Ran Zhuo1, Colette J. Matysiak Match1, Sanchi Malhotra, Huan Vinh Dong, Kristina Adachi, Robert S. Venick, Grace Aldrovandi, and Shangxin YangComments to Author 
Author affiliation: University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA (R. Zhuo, C.J. Matysiak Match, S. Malhotra, H.V. Dong, K. Adachi, R.S. Venick, G. Aldrovandi, S. Yang); Duke University School of Medicine, Durham, North Carolina, USA (R. Zhuo); University of California San Francisco School of Medicine, San Francisco, California, USA (C.J.M. Match)

Main Article

Figure

Longitudinal human adenovirus species F type 41 viral loads measured by quantitative PCR in whole-blood specimens from 2 pediatric cases of acute severe hepatitis of unknown etiology associated with adeno-associated virus type 2 and human adenovirus species F type 41 co-infection, California, USA. Viral loads are plotted against hospital day, illustrating high viremia preceding antiviral therapy and liver transplantation in case 1, the subsequent decline during cidofovir treatment, and persistent low-level detection despite clinical improvement in case 2.

Figure. Longitudinal human adenovirus species F type 41 viral loads measured by quantitative PCR in whole-blood specimens from 2 pediatric cases of acute severe hepatitis of unknown etiology associated with adeno-associated virus type 2 and human adenovirus species F type 41 co-infection, California, USA. Viral loads are plotted against hospital day, illustrating high viremia preceding antiviral therapy and liver transplantation in case 1, the subsequent decline during cidofovir treatment, and persistent low-level detection despite clinical improvement in case 2.

Main Article

1These authors contributed equally to this article.

Page created: May 06, 2026
Page updated: May 12, 2026
Page reviewed: May 12, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external